Davita Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Vanguard International High Dividend Yield ETF trades at $100.25 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 2× Davita Inc's market cap, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| DVA | VYMI | |
|---|---|---|
Market Cap | $11.29B | $22.80B |
Volume | 582,204 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $107.13 |
52-Week Low | $103.87 | $82.92 |
Typical Hold Time | 113 Days | 50 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
VYMI trades at $100.23, down 1.11% today amid bearish technical signals. The ETF shows strong institutional interest with multiple firms increasing holdings recently. Recent analysis highlights VYMI's 5-year average annual return of 14.13% and 3.61% dividend yield, outperforming peers despite current technical weakness.
The outlook remains positive given VYMI's exposure to international dividend stocks benefiting from higher global rates. Key risks include currency fluctuations and concentrated financial sector exposure. Analyst sentiment leans bullish with expectations of continued international stock outperformance versus US markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →